North News
New Delhi, September 12
The Drug Controller General of India (DCGI) has suspended the manufacturing and marketing license for PresVu, an Indian eye drop product that claimed to replace reading glasses for people with presbyopia. The suspension follows allegations of unauthorized claims made by the company. According to the DCGI, the company “failed to respond to queries and attempted to justify claims for which no approval was granted.”
The DCGI clarified that while PresVu is approved for presbyopia, it was not authorized to claim that it provides advanced near vision improvement within 15 minutes. Entod Pharmaceuticals, the maker of PresVu, denied any unethical promotion and plans to challenge the suspension in court. CEO Nikkhil Masurkar stated in a press release that announcing new products to the media is a standard industry practice, and the controversy arose from media reports and public reaction. He emphasized that similar descriptive practices are common in press releases from other pharmaceutical companies.
